2011 Scrip Asia 100 - TeloVac tailwind helps KAEL-GemVax chart a course to market
This article was originally published in Scrip
Being part of a large listed group relieves KAEL-GemVax from the constant fundraising headaches typical of its peers, writes Ian Haydock. This article is part of the 2011 Scrip Asia 100.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.
Amid simmering regional geopolitical tensions, speakers at a recent conference highlighted the multiple benefits of conducting clinical trials in Taiwan, while pointing to what more could be done to improve the local ecosystem.
In this week's podcast version of Five Must-Know Things: BMS’s new products meet early expectations; Eisai to shut a US unit in global R&D restructuring; Roche aims high for Vabysmo; US priority review for Biogen’s ALS contender; and a chat with Gennova’s CEO.